Oliver Smart is now with Global Phasing and HOLE is supported
by/available from the Sansom lab at Oxford:
http://hole.biop.ox.ac.uk/hole
Quoting "Hargreaves, David" <[log in to unmask]>:
> Dear CCP4,
>
> I'm looking for the authors of the programs (listed below). I want to
> analyse our crystal systems and would like to use these algorithms.
> However, I'm not convinced the addresses on the papers are current.
>
> Does anybody know how to contact the authors or of any other programs
> that exist for these calculations?
>
> Is there anything in the CCP4 arsenal for this purpose?
>
> I'm happy to be contacted directly.
>
>
>
> Thanks,
>
>
>
> Dave
>
>
>
> "HOLE: A program for the analysis of the pore dimensions of ion channel
> structural models"
>
> Oliver S. Smart, Joseph G. Neduvelil, Xiaonan Wang, B. A. Wallace, Mark
> S. P. Sansomt
>
> J. Mol. Graphics, 1996, vol14
>
>
>
>
>
> "An algorithm to find channels and cavities within protein crystals
> (CHANNEL)": Oleg S. Kisljuk, Galina S. Kachalova and Nadejda Ph. Lanina
>
> J. Mol. Graphics, 1994, vol12
>
>
>
>
>
> David Hargreaves
>
> Associate Principal Scientist
>
> _____________________________________________________________________
>
> AstraZeneca
>
> DECS, CP&SS
>
> Mereside, 50F49, Alderley Park, Cheshire, SK10 4TF
>
> Tel +44 (0)01625 518521 Fax +44 (0) 1625 232693
>
> David.Hargreaves @astrazeneca.com <mailto:[log in to unmask]>
>
>
>
> Please consider the environment before printing this e-mail
>
>
>
>
> --------------------------------------------------------------------------
> AstraZeneca UK Limited is a company incorporated in England and
> Wales with registered number: 03674842 and a registered office at 2
> Kingdom Street, London, W2 6BD.
> Confidentiality Notice: This message is private and may contain
> confidential, proprietary and legally privileged information. If you
> have received this message in error, please notify us and remove it
> from your system and note that you must not copy, distribute or take
> any action in reliance on it. Any unauthorised use or disclosure of
> the contents of this message is not permitted and may be unlawful.
> Disclaimer: Email messages may be subject to delays, interception,
> non-delivery and unauthorised alterations. Therefore, information
> expressed in this message is not given or endorsed by AstraZeneca UK
> Limited unless otherwise notified by an authorised representative
> independent of this message. No contractual relationship is created
> by this message by any person unless specifically indicated by
> agreement in writing other than email.
> Monitoring: AstraZeneca UK Limited may monitor email traffic data
> and content for the purposes of the prevention and detection of
> crime, ensuring the security of our computer systems and checking
> Compliance with our Code of Conduct and Policies.
>
----------------------------------------------------------------
This message was sent using IMP, the Internet Messaging Program.
|